Fresenius Medical Care AG (NYSE:FMS) Shares Bought by JPMorgan Chase & Co.

JPMorgan Chase & Co. grew its holdings in Fresenius Medical Care AG (NYSE:FMS) by 18.2% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 9,902 shares of the company’s stock after buying an additional 1,528 shares during the period. JPMorgan Chase & Co.’s holdings in Fresenius Medical Care were worth $211,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in FMS. Allworth Financial LP boosted its position in shares of Fresenius Medical Care by 53.1% during the 3rd quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock worth $36,000 after purchasing an additional 581 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Fresenius Medical Care in the third quarter valued at about $38,000. GAMMA Investing LLC boosted its holdings in Fresenius Medical Care by 50.4% during the third quarter. GAMMA Investing LLC now owns 4,998 shares of the company’s stock worth $106,000 after buying an additional 1,675 shares in the last quarter. ORG Wealth Partners LLC acquired a new position in Fresenius Medical Care during the third quarter worth about $112,000. Finally, Venturi Wealth Management LLC increased its holdings in Fresenius Medical Care by 1,045.8% in the third quarter. Venturi Wealth Management LLC now owns 5,259 shares of the company’s stock valued at $112,000 after buying an additional 4,800 shares in the last quarter. Institutional investors and hedge funds own 8.37% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. Bank of America upgraded shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a report on Monday, December 2nd. Berenberg Bank began coverage on Fresenius Medical Care in a research report on Wednesday, November 6th. They set a “buy” rating and a $25.60 price objective for the company. StockNews.com initiated coverage on Fresenius Medical Care in a research note on Friday, January 3rd. They issued a “strong-buy” rating on the stock. Finally, Truist Financial boosted their price target on Fresenius Medical Care from $23.00 to $25.00 and gave the stock a “hold” rating in a report on Monday, January 6th.

Fresenius Medical Care Stock Performance

Fresenius Medical Care stock opened at $24.89 on Friday. Fresenius Medical Care AG has a 52 week low of $17.93 and a 52 week high of $25.25. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. The stock has a market cap of $14.60 billion, a P/E ratio of 20.57, a price-to-earnings-growth ratio of 0.82 and a beta of 0.92. The stock has a 50 day moving average of $23.14 and a 200-day moving average of $21.18.

Fresenius Medical Care (NYSE:FMS) last posted its quarterly earnings results on Tuesday, November 5th. The company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.42 by $0.03. The business had revenue of $5.23 billion during the quarter, compared to analyst estimates of $5.36 billion. Fresenius Medical Care had a net margin of 3.43% and a return on equity of 6.04%. During the same period in the previous year, the business posted $0.31 EPS. On average, analysts expect that Fresenius Medical Care AG will post 1.53 EPS for the current fiscal year.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.